# Ticagrelor Single Antiplatelet Therapy in Patients With High Risk of Bleeding After DCB for Coronary Small Vessel Disease

> **NCT06088433** · PHASE4 · UNKNOWN · sponsor: **Fu Wai Hospital, Beijing, China** · enrollment: 292 (estimated)

## Conditions studied

- Coronary Heart Disease

## Interventions

- **DRUG:** Ticagrelor
- **DRUG:** Clopidogrel
- **DRUG:** Aspirin

## Key facts

- **NCT ID:** NCT06088433
- **Lead sponsor:** Fu Wai Hospital, Beijing, China
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-11-15
- **Primary completion:** 2024-11-30
- **Final completion:** 2025-11-30
- **Target enrollment:** 292 (ESTIMATED)
- **Last updated:** 2023-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06088433

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06088433, "Ticagrelor Single Antiplatelet Therapy in Patients With High Risk of Bleeding After DCB for Coronary Small Vessel Disease". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT06088433. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*